ANRI is a Tokyo-based independent venture capital firm founded in 2012 by Anri Samata. See stage focus and contact routes.
ANRI is a Tokyo-based independent venture capital firm founded in 2012 by Anri Samata, recognized as one of Japan’s largest seed-stage investors. The firm’s investment thesis targets seed and early-stage Japanese startups, with a focus on sectors including healthcare, consumer, fintech, internet, and deep tech. ANRI typically writes checks between $100,000 and $5 million, with a sweet spot around $1.5 million, and often acts as a lead investor in early rounds. Notable portfolio companies include N.B.Medical, which received a $5.0M Series B investment from ANRI in March 2026, as well as over 200 other startups supported since inception. The firm manages over ¥70 billion in cumulative assets under management, including its ¥30 billion fifth flagship fund and a targeted ¥50 billion sixth fund. ANRI distinguishes itself through a strong emphasis on supporting female founders and maintaining close collaboration with entrepreneurs, guided by the motto “CHANGE before YOU HAVE TO”.
Details on this firm come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in Tokyo.
Investors like Anri · Full investor directory · Investor access · Company funding database